The firm will use the funds to advance its mRNA therapies, including its lead candidate STX-001 for treating melanoma and triple-negative breast cancer.

The firm recently had a successful end-of-Phase II meeting with the FDA, in which the agency provided feedback into a Phase III trial design.

In a combined analysis of patients from five open-label trials, 22 percent responded to the protease activator, the first approved treatment for the rare disease.